weight gain on semaglutide Simple “gut reset” may stop after Ozempic or Wegovy Why Am I Not Losing

These findings suggest that GPX3 may play a crucial role in the reduction of extracellular ROS

This is a significant development as sleep apnea is common in this population and contributes to cardiovascular risk

How do these shots work, and what makes them different

As the new Alzheimers results show, theres been a disconnect between the outcomes of large studies like these and other evidence pointing to potential benefits

Many Canadians report significant pain reduction within the first two weeks of consistent use

The bottom line: Our findings suggest that GLP-1RA and SGLT2i (and especially SGLT2i with the lowest number needed to treat (NNT) for nearly all study outcomes) may be the preferred glucose-lowering agents for cardiovascular risk reduction in patients at moderate risk for CVD, building on and consistent with existing RCT evidence in the high-risk population. This report highlights potential preference for GLP-1 drugs as a first-line treatment for Type 2 diabetes related to its cardioprotective effect